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hypermutator USC experience a signiﬁcantly better prognosis when
compared to the remaining USC patients (Fig. 1). These results were
surprising considering that 2 of 5 of the long term USC survivors in
our series harbored advanced stage disease (i.e., stage III) and the re-
maining 3 stage IB disease (risk of recurrence up to 80%) (Fader et al.,
2013). Importantly, the survival results we report in patients harboring
hypermutator Type II USChave recently been conﬁrmed by the similarly
excellent survival results found in 7% (17 out of 248) of the Type I endo-
metrial cancer patients harboring proofreading POLE mutations report-Fig. 1. Survival analysis ofUSC patients. Kaplan–Meyers survival curves for 57USCpatientsBrief communication
Uterine serous carcinoma (USC) is a rare but highly aggressive
subtype of endometrial cancer causing a disproportionate number of
cancer-related deaths. The overall 5-year survival of USC is only 30 ±
9% for all stages and the recurrence rate after surgery is extremely
high (50–80%) (Fader et al., 2013).
We have recently sequenced the exomes of a large cohort of com-
prehensively staged USC all uniformly treated per Institutional guide-
lines with adjuvant brachytherapy and/or pelvic radiation followed by
six cycles of carboplatin/paclitaxel (Fader et al., 2013; Zhao et al.,
2013). Within the 57 USC patients we identiﬁed a subset of patients
(5/57 = 8.7%) demonstrating a hypermutator phenotype (i.e., greater
than 4000 protein-altering somatic mutations per tumor) (Zhao et al.,
2013). This was in strong contrast to the substantially reduced number
of somatic mutations (i.e., less than 100) identiﬁed in the remaining
52 USC patients (Zhao et al., 2013). All hypermutator USC harbored
somatic mutations in the DNA polymerase ε gene (Zhao et al., 2013), a
primary guardian of DNA replication ﬁdelity during cell division recently
shown to confer a strong mutator phenotype and high incidence of
spontaneous neoplasms in mice (Albertson et al., 2009) and humans
(Palles et al., 2013). Examination of the POLE and MMR genes showed
no germ-line mutations; however, somatic mutations in these genes
were highly prevalent in these tumors (mean of 4 per tumor, including
4 premature termination mutations for MMR genes and a mean of 4.5
per tumor for POLE) and more frequent than expected by chance
(P = 2.23 × 10− 3) (Zhao et al., 2013).& Gynecology, Yale University
t, PO Box 208063, New Haven,
in).
. This is an open access article undered by the TCGA group (The Cancer Genome Atlas Research Network,
2013) and in 15% (8 out of 53) grade 3 endometrioid adenocarcinoma
of the endometrium reported by Meng et al. (2014).
While it is currently not understood why patients developing
hypermutator Type I (The Cancer Genome Atlas Research Network,
2013; Meng et al., 2014) and Type II (USC) endometrial cancers may
experience such a good prognosis, it is possible that the high number
of somatic mutations present in these tumors may render these cancers
highly immunogenic for the host due to the large number of mutated
epitopes. Alternatively, these cancers might be differentially sensitive
to standard adjuvant treatments (i.e., radiation and/or chemotherapy).(5 harboring a hypermutator phenotype vs 52 moderately mutated) according to mixed
and pure tumor histology. The median (range) duration of follow-up was 24 (1–141)
months in the USC patients while the median (range) of follow up was 71 (16–119)
months in the POLE patients. P value was calculated by the log-ranked test for survival
differences. Secondary to the low number of patients in the POLE mutated subset, a
comparison for stage is not feasible.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
4 A.D. Santin et al. / Gynecologic Oncology Reports 12 (2015) 3–4These data provide novel information for the identiﬁcation of a
subset of biologically aggressive USC with unique prognostic features
and biological properties. It will be of great interest to determinewhether
the POLEmutationswe found inUSC are of similar prognostic signiﬁcance
in the multiple additional types of human cancers recently found by
the TCGA network to harbor POLE mutations (https://tcga-data.nci.nih.
gov/tcga/).
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